Dexanabinol

Drug Overview

Dexanabinol is a synthetic, specialized molecule that was originally developed to protect the brain and nervous system from damage. While it is related to compounds found in the cannabis plant, it is a “non-psychotropic” version. This means it does not cause the “high” associated with marijuana. In medical research, it is often called a “neuroprotective agent” and is being studied as a potential “Targeted Therapy” for certain types of aggressive tumors.

Here are the key details about this medication:

• Generic Name: Dexanabinol (also known as HU-211).
• US Brand Names: None. It is currently an investigational drug.
• Drug Class: Synthetic Cannabinoid Derivative / NMDA Receptor Antagonist / Anti-inflammatory Agent.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. It is not currently FDA-approved for general public use but is being studied in clinical trials for brain injury and advanced cancer.

What Is It and How Does It Work? (Mechanism of Action)

To understand how dexanabinol works, it helps to look at how cells send distress signals. When the brain or a tumor is under stress, it releases a chemical called glutamate. While glutamate is normally helpful, too much of it can over-excite cells until they die. Dexanabinol acts like a safety valve to prevent this.

Blocking the NMDA Receptor

At the molecular level, dexanabinol is a “non-competitive antagonist” of the NMDA (N-methyl-D-aspartate) receptor.

1. The Overload Problem: In many brain injuries and cancers, NMDA receptors are stuck in the “on” position, allowing too much calcium to flow into the cells. This calcium overload triggers enzymes that chew up the cell from the inside.
2. The Shield Effect: Dexanabinol sits on the receptor and blocks this toxic calcium flow. Unlike some other blockers, it only works when the receptor is overactive, which makes it safer for healthy cells.
   

Anti-Inflammatory Signaling

Beyond the NMDA receptor, dexanabinol interferes with a “master switch” for inflammation called TNF-alpha (Tumor Necrosis Factor-alpha).

• Blocking Cytokines: It stops the production of certain pro-inflammatory chemicals (cytokines).
• Starving the Tumor: In cancer, inflammation often helps a tumor grow and hide from the immune system. By lowering these inflammatory signals, dexanabinol may help slow down tumor progression and reduce the swelling often seen in brain tumors.

FDA-Approved Clinical Indications

Because dexanabinol is an investigational agent, it does not have “official” FDA-approved uses for routine prescription. It is currently being utilized in strictly controlled clinical trials for the following:

Oncological Uses (In Clinical Trials):

• Glioblastoma Multiforme: A highly aggressive brain cancer.
• Advanced Solid Tumors: Used in patients whose cancer has not responded to standard treatments.
• Brain Metastases: Cancers that have spread to the brain from other parts of the body.

Non-oncological Uses (In Clinical Trials):

• Traumatic Brain Injury (TBI): Historically studied to reduce brain swelling after accidents.
• Post-Operative Cognitive Dysfunction: To protect the brain during major surgeries.

Dosage and Administration Protocols

As an investigational drug, the dose of dexanabinol is carefully calculated by doctors based on the specific goals of the research study. It is given directly into the bloodstream through an IV.

Note: There are no standard dose adjustments for kidney or liver issues yet, as these are still being determined in Phase I and Phase II trials.

Clinical Efficacy and Research Results

Recent clinical research (2020–2025) has shifted focus toward how dexanabinol can help patients with brain cancer.

• Tumor Stabilization: In early-phase trials for glioblastoma, a small percentage of patients experienced “stable disease.” This means the tumor stopped growing for a period of time, even if it did not shrink significantly.
• Survival Data: For patients with very advanced tumors who had failed 3 or more previous therapies, some studies showed a median progression-free survival (the time before the cancer starts growing again) of approximately 2 to 3 months.
• Safety Success: The most important result from recent studies is that dexanabinol is “well-tolerated.” Unlike many chemotherapy drugs, it does not typically cause the severe hair loss or extreme vomiting that patients fear most.

Safety Profile and Side Effects

Because dexanabinol is designed to be gentle on healthy tissue, its side effect profile is different from traditional chemotherapy.

Black Box Warning: There is no FDA Black Box Warning for dexanabinol as it is not yet an approved medication.

Common Side Effects (>10%)

• Fatigue: A general feeling of tiredness or weakness.
• Nausea: Feeling sick to the stomach, usually mild.
• Headache: Mild pressure or pain in the head.
• Dizziness: Feeling lightheaded shortly after the infusion.

Serious Adverse Events

• Liver Enzyme Changes: Some patients show an increase in liver proteins on blood tests, which may indicate the liver is working harder to process the drug.
• Infusion Reactions: Mild rashes or blood pressure changes during the IV administration.

Management Strategies

• For Dizziness: Patients are asked to remain seated or lying down for at least one hour after the infusion finishes.
• For Liver Health: Doctors perform weekly blood tests to ensure the liver is staying healthy. If enzymes rise too high, the drug is paused.

Research Areas

Dexanabinol is currently a major topic in Immunotherapy and Neuro-Regeneration research.

Scientists are exploring whether dexanabinol can “prime” the environment around a brain tumor to make it more sensitive to other treatments. In regenerative medicine, researchers are looking at whether the drug can protect “neural stem cells”—the cells responsible for repairing brain tissue—from the harsh effects of radiation therapy. By protecting these healthy stem cells, doctors hope to help patients keep their memory and thinking skills better during and after cancer treatment.

Patient Management and Practical Recommendations

To ensure safety and the best possible results, patients in dexanabinol trials follow strict guidelines.

Pre-treatment Tests to be Performed

• MRI Scan: A detailed picture of the brain or tumor area to use as a baseline.
• Comprehensive Blood Panel: To check the starting health of the liver and kidneys.
• Pregnancy Test: Required for women of childbearing age, as the effects on an unborn baby are unknown.

Precautions During Treatment

• Driving: You should not drive yourself home after an infusion due to the risk of temporary dizziness or lightheadedness.
• Other Medications: Some medications that affect the brain (like certain anti-seizure drugs) might interact with dexanabinol. Always provide your doctor with a full list of your medications.

“Do’s and Don’ts” List

• DO drink plenty of water on the day of your infusion to help your kidneys.
• DO report any new or worsening neurological symptoms (like numbness or confusion) to your team immediately.
• DON’T use any cannabis-based products (CBD or THC) while on this study, as it can confuse the results.
• DON’T skip your scheduled blood tests; they are the “early warning system” for your liver.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Dexanabinol is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.